SLN
Silence Therapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$14.59
−1.35%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 311.18x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 22.83x
- Price / sales
- 1430.03x
- Price / cash flow
- -20.77x
Enterprise value
- Enterprise value
- $806.5M
- EV / sales
- 1312.92x
- EV / EBITDA
- -13.38x
- EV / EBIT
- -12.07x
- Market cap
- $878.5M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026